Royal Bank Of Canada Upgrades CSL (OTCMKTS:CSLLY) to “Moderate Buy”

CSL (OTCMKTS:CSLLY) was upgraded by Royal Bank Of Canada from a “hold” rating to a “moderate buy” rating in a note issued to investors on Monday,Zacks.com reports.

A number of other brokerages have also recently issued reports on CSLLY. Zacks Research raised shares of CSL from a “strong sell” rating to a “hold” rating in a report on Monday, December 29th. Canaccord Genuity Group upgraded CSL from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy”.

CSL Price Performance

OTCMKTS CSLLY opened at $59.31 on Monday. The firm’s fifty day moving average price is $58.93 and its two-hundred day moving average price is $67.93. CSL has a 1 year low of $54.10 and a 1 year high of $89.71. The company has a quick ratio of 1.12, a current ratio of 2.46 and a debt-to-equity ratio of 0.50.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.